Dario C. Altieri Joins Jefferson as Faculty, Elevating Cancer Research Excellence

Dario C. Altieri Elevates Cancer Research at Jefferson University

Thomas Jefferson University has recently appointed Dr. Dario C. Altieri, an esteemed figure in cancer research, to its faculty at the Sidney Kimmel Medical College. His official tenure starts on January 1, 2027, marking a significant enhancement to the institution's oncology programs.

Dr. Altieri joins Jefferson from The Wistar Institute, where his leadership contributed to the institution's excellence in cancer research. He will serve as a Professor in both the Department of Pharmacology, Physiology and Cancer Biology, and the Department of Biochemistry and Molecular Biology. Additionally, he has been designated as Special Advisor to the Director of the Sidney Kimmel Comprehensive Cancer Center. This appointment underlines Jefferson’s commitment to forging pathways within cancer biology that aim to translate laboratory findings to real-world applications.

A respected physician-scientist, Dr. Altieri's research has fundamentally advanced our understanding of tumor biology. He has particularly focused on survivin, an Inhibitor of Apoptosis (IAP) gene that is commonly overproduced in various cancers. His investigations delve into how this gene influences cancer cell survival, alongside studying the mechanisms by which cancer cells develop resistance to therapies. His goal is to pioneer new treatment strategies that fortify cancer care and efficacy.

Celebrating Dr. Altieri's Contributions

Dr. Said Ibrahim, Dean of the Sidney Kimmel Medical College and President of Jefferson University Physicians, expressed enthusiasm about Dr. Altieri's arrival. “Jefferson has long been home to world-class research, and Dr. Altieri's arrival deepens that tradition in a meaningful way,” he stated. Dr. Ibrahim emphasized Altieri’s significant contributions to the cancer field, noting his extensive experience in training the next generation of scientists and advancing clinical applications of research.

In response to his new role, Dr. Altieri noted, “It is a great honor to have the opportunity to join the Sidney Kimmel Comprehensive Cancer Center. Jefferson’s dedication to scientific discovery and patient care aligns perfectly with my own aspirations.” His transition back into laboratory-focused research comes at a time when he seeks to enhance Jefferson’s profile as a hub for innovative cancer research.

Achievements at Wistar Institute

As President and CEO of The Wistar Institute, Dr. Altieri led numerous initiatives that boosted its global reputation in oncology. His leadership saw transformative advancements, including a tripling of the endowment and the establishment of new research centers. His tenure has been recognized as instrumental in bridging the gap between scientific research and clinical application, reflecting his dedication to improving patient outcomes.

Rick Horowitz, Chair of the Wistar Institute Board of Trustees, commended Altieri’s leadership, remarking, “Dario has been an extraordinary leader for Wistar, instrumental in cutting-edge research.” He acknowledged Altieri's contributions and the sustained impact on various domains within cancer research, infectious diseases, and immunology.

Dr. Altieri’s Academic Journey

Dr. Altieri’s educational background includes a medical degree from the University of Milan. He developed his expertise through extensive training in internal medicine and clinical hematology, alongside notable research roles, including at the Scripps Clinic. His previous academic roles included a Professorship at Yale University and leadership in cancer biology at the University of Massachusetts.

In addition to his research contributions, Dr. Altieri advocates for the next generation of scientists and plays an active role in the cancer research community. He co-founded significant movements like the Cancer Biology Training Consortium and the Pancreatic Cancer Alliance, underlining his commitment to advancing cancer research and patient education.

As Dr. Altieri prepares to join the ranks of Jefferson University, both institutions celebrate this collaboration as a strategic move that promises to bolster New Jersey and Pennsylvania’s life science sectors and enhance the broader impact on cancer therapeutics and patient care. His leap is viewed as one filled with possibilities that will contribute to transformative cancer research and ensure that discoveries are translated effectively into clinical practice.